The Patient-Reported Outcomes Measurement Information Systems (PROMIS) Global Health (PGH) assessment, which includes 5 primary physical and mental health domains, was valid and feasible for the assessment of health-related quality of life (HRQoL) in adult patients with atopic dermatitis (AD), according to study data published in the Journal of the American Academy of Dermatology.

This prospective dermatology-practice study included 994 patients with AD (mean age, 44.7 years) who were recruited from an eczema clinic at a single center. All patients received standard-of-care treatment, such as emollients, prescription topical therapy, systemic therapy, and/or phototherapy. At each encounter, patients answered questions on the PGH assessment, self-reported the severity of their disease, and rated their 7-day itch severity using a 0 to 10 numeric rating scale (NRS) and verbal rating scale (VRS). Additional questionnaires administered at each encounter included the 10-question DLQI and 9-question Patient-Health Questionnaire-9 (PHQ-9).

A dermatologist also performed full-body skin evaluations of each patient. Researchers assessed the clinician-reported outcomes Eczema Area and Severity Index (EASI), Scoring AD (SCORAD), and objective component of the SCORAD.

Continue Reading

In terms of concurrent validity, the investigators found very strong correlations with PGH-P4 T scores with its PGH-P2 (rho=0.88) and PGH mental T-scores (rho=0.64). Strong correlations were also found between PGH physical health (PGH-P2) and PGH mental health (PGH-M2) T-scores (rho=0.60) (P <.0001 for all). In addition, Euroqol-5D health utility score (mEQ-5D) held the strongest correlation with the PGH-P4 (rho=0.89; P <.0001) as well as very strong correlations with PGH-M4 T-score (rho=0.81; P <.0001), PGH-P2 (rho=0.72; P <.0001), and PGH-M2 (rho=0.72; P <.0001) T-scores.

The PGH-P4 T-scores also held strong correlations with PO-SCORAD, PROMIS SD, and PHQ-9, as well as moderate correlations with POEM, NRS worst-itch and average-itch, DLQI, EASI, SCORAD, and objective-SCORAD (P <.0001). In terms of validity, the investigators observed significant and stepwise increases of PGH-P4, PGH-M4, PGH-P2, PGH-M2 T-scores, and mEQ-5D scores at each severity level for self-reported global severity (P <.0001).

Limitations of this study were the inclusion of patients from a single center and the use of a single question to determine race and ethnicity.

The researchers concluded that the studied “instruments may provide important information about overall HRQOL that can guide therapeutic decision-making.”

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors’ disclosures.


Schwartzman G, Lei D, Yousaf M, et al. Validity and reliability of patient-reported outcomes measurement information system global health scale in adults with atopic dermatitis. Published online January 20, 2021. J Am Acad Dermatol. doi:10.1016/j.jaad.2021.01.033